Your session is about to expire
← Back to Search
Chemotherapy + TKI for Acute Lymphoblastic Leukemia
Study Summary
This trial will study the safety and efficacy of a combination of standard chemotherapy and tyrosine kinase inhibitors (TKIs) in adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't taken strong CYP3A4 affecting drugs or supplements recently.I do not have serious heart problems, uncontrolled high blood pressure, severe pancreas issues, or ongoing severe nausea.I have a history of HIV, Hepatitis B, or Hepatitis C.My leukemia is B-Cell ALL and does not have the Philadelphia chromosome.My leukemia is T-cell based.My leukemia has returned after treatment.My leukemia is identified as Mature B-Cell (Burkitt's).I am 18 years old or older.My kidney function is low, but it's due to my cancer or treatment and can be treated.I can care for myself and am eligible for strong chemotherapy.My cancer is positive for the Philadelphia chromosome.My heart's pumping ability is confirmed to be less than 45%.I agree to use effective birth control during and up to 30 days after the trial.My condition is a severe phase of chronic myeloid leukemia.My leukemia has spread to my brain or testes.I do not have a history of serious bleeding disorders.I haven't needed treatment for any cancer other than ALL in the last 2 years, except for certain skin cancers or early-stage cancers.I haven't been treated for my condition, except possibly with corticosteroids, hydroxyurea, or leukapheresis just after diagnosis.I have been recently diagnosed with Ph+ acute lymphoblastic leukemia.My cancer is of B-Cell origin according to tests.I show symptoms of a brain or spinal cord condition.
- Group 1: BFM + Tyrosine Kinase Inhibitor
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA issued a stamp of approval for Dasatinib?
"As it is a Phase 2 trial, there are data points demonstrating its safety but not yet proving efficacy; for this reason, Dasatinib was given a score of 2."
How many participants are actively enrolled in this study?
"Affirmative. Clinicaltrials.gov verifies that this clinical trial, which was first published on October 1st 2022, is actively looking for subjects. 23 individuals need to be signed up from one medical centre."
Is enrollment for this medical experiment currently available?
"Affirmative. According to the records on clinicaltrials.gov, this medical trial is in search of 23 volunteers from a single site location since it was initially posted on October 1st 2022 and edited most recently on August 31st 2022."
What is the customary application of Dasatinib?
"Dasatinib is mainly used to combat small cell lung cancer, but also have success in treating active pauciarticular juvenile rheumatoid arthritis, multiple sclerosis, and head and neck carcinoma."
Share this study with friends
Copy Link
Messenger